Ubs Group Ag Aytu Biopharma, Inc Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.15 - $4.0 $7,800 - $208,004	-52,001 Reduced 90.88%	5,218 $0
Q3 2022 Nov 10, 2022	BUY	$0.19 - $3.8 $9,706 - $194,134	51,088 Added 833.27%	57,219 $11,000
Q2 2022 Aug 10, 2022	BUY	$0.46 - $1.08 $2,819 - $6,620	6,130 Added 613000.0%	6,131 $4,000
Q1 2022 May 16, 2022	SELL	$1.08 - $1.55 $15,801 - $22,678	-14,631 Reduced 99.99%	1 $0
Q4 2021 Feb 14, 2022	BUY	$1.35 - $2.95 $17,617 - $38,497	13,050 Added 824.91%	14,632 $20,000
Q3 2021 Nov 15, 2021	BUY	$2.78 - $5.12 $1,843 - $3,394	663 Added 72.14%	1,582 $5,000
Q2 2021 Aug 13, 2021	SELL	$4.73 - $7.56 $8,244 - $13,177	-1,743 Reduced 65.48%	919 $5,000
Q1 2021 May 12, 2021	SELL	$6.23 - $9.88 $27,455 - $43,541	-4,407 Reduced 62.34%	2,662 $20,000
Q4 2020 Feb 11, 2021	BUY	$5.98 - $13.5 $42,272 - $95,431	7,069 New	7,069 $42,000

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $97.4M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.